ANDA 90116, held by Chartwell Molecular. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 90116 (Ondansetron Hydrochloride), held by Chartwell Molecular, was first approved by FDA on Apr 14, 2010, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 14, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Apr 19, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 19, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 2, 2016 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 2, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 16, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 8, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 10, 2012 | Supplement 3Labeling | Approved | None posted |
| Sep 30, 2011 | Supplement 2Labeling | Approved | None posted |
| Jul 22, 2011 | Supplement 1Labeling | Approved | None posted |
| Apr 14, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters